FDA加速批准图卡替尼联合曲妥珠单抗用于结直肠癌
正文 · 中文译文
FDA加速批准图卡替尼联合曲妥珠单抗用于结直肠癌 癌症批准 肿瘤(癌症)/血液系统恶性肿瘤批准通知 进行中 | 癌症加速批准 已证实临床获益 | 癌症加速批准 已撤回 | 癌症加速批准 其他 | 癌症加速批准 2023年1月19日,美国食品药品监督管理局(FDA)加速批准图卡替尼(Tukysa,Seagen公司)联合曲妥珠单抗用于RAS野生型HER2阳性、不可切除或转移性结直肠癌,且既往接受氟尿嘧啶类、奥沙利铂和伊立替康为基础的化疗后进展的患者。 查看Tukysa完整处方信息 疗效在MOUNTAINEER(NCT03043313)这项开放标签、多中心试验的84例患者中进行了评估。患者须为HER2阳性、RAS野生型、不可切除或转移性结直肠癌,且既往接受过氟尿嘧啶类、奥沙利铂、伊立替康和抗血管内皮生长因子(VEGF)单克隆抗体(mAb)治疗。错配修复缺陷(dMMR)蛋白或微卫星高度不稳定(MSI-H)的肿瘤患者还必须接受过抗程序性细胞死亡蛋白-1单克隆抗体治疗。既往接受过抗HER2靶向治疗的患者被排除。 患者接受图卡替尼300 mg口服,每日两次,联合曲妥珠单抗(或非美国批准的曲妥珠单抗产品),第1周期第1天静脉给予负荷剂量8 mg/kg,随后每个后续21天周期的第1天给予曲妥珠单抗维持剂量6 mg/kg。患者接受治疗直至疾病进展或出现不可接受的毒性。 主要疗效指标为经盲法独立中心审查(RECIST版本1.1)评估的客观缓解率(ORR)和缓解持续时间(DOR)。ORR为38%(95% CI:28,49),中位DOR为12.4个月(95% CI:8.5,20.5)。 最常见的不良事件(≥20%)为腹泻、疲乏、皮疹、恶心、腹痛、输液相关反应和发热。最常见的实验室异常(≥20%)为肌酐升高、葡萄糖升高、ALT升高、血红蛋白降低、AST升高、胆红素升高、碱性磷酸酶升高、淋巴细胞降低、白蛋白降低、白细胞降低和钠降低。 推荐的图卡替尼剂量为300 mg口服,每日两次,与曲妥珠单抗联合使用,直至疾病进展或出现不可接受的毒性。 本审查在Project Orbis下进行,该项目是美国食品药品监督管理局(FDA)肿瘤卓越中心的一项倡议。Project Orbis为国际合作伙伴之间肿瘤药物的同步提交和审查提供了框架。在本审查中,FDA与澳大利亚治疗用品管理局(TGA)合作。该申请的审查在其他监管机构仍在进行中。 本综述使用了评估辅助工具(Assessment Aid),这是申请人自愿提交的材料,旨在便于FDA进行评估。 本申请获得了优先审评和突破性疗法认定。FDA加速审评项目在《行业指南:严重疾病药物和生物制品的加速审评项目》中有详细描述。Tukysa获得了用于治疗HER2+结直肠癌的孤儿药认定。 医疗专业人员应将所有怀疑与任何药物和器械使用相关的严重不良事件报告至FDA的MedWatch报告系统,或致电1-800-FDA-1088。 如需获得研究性肿瘤产品单患者IND方面的协助,医疗专业人员可联系OCE的Project Facilitate,电话240-402-0004,或发送电子邮件至OncProjectFacilitate@fda.hhs.gov。 关于COVID-19大流行的信息,请参阅以下资源: FDA:冠状病毒病2019(COVID-19) NCI:冠状病毒:癌症患者应了解的内容 CDC:冠状病毒(COVID-19) 在Twitter上关注肿瘤学卓越中心 @FDAOncology。 内容截至日期: 01/19/2023 受监管产品 药物 肿瘤学
正文 · 英文原文
FDA grants accelerated approval to tucatinib with trastuzumab for colorectal cancer Cancer Approvals Oncology (Cancer)/Hematologic Malignancies Approval Notifications Ongoing | Cancer Accelerated Approvals Verified Clinical Benefit | Cancer Accelerated Approvals Withdrawn | Cancer Accelerated Approvals Other | Cancer Accelerated Approvals On January 19, 2023, the Food and Drug Administration (FDA) granted accelerated approval to tucatinib (Tukysa, Seagen Inc.) in combination with trastuzumab for RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. View full prescribing information for Tukysa Efficacy was evaluated in 84 patients in MOUNTAINEER (NCT03043313), an open-label, multicenter trial. Patients were required to have HER2-positive, RAS wild-type, unresectable or metastatic colorectal cancer and prior treatment with fluoropyrimidine, oxaliplatin, irinotecan, and an anti-vascular endothelial growth factor (VEGF) monoclonal antibody (mAb). Patients whose tumors were deficient in mismatch repair (dMMR) proteins or were microsatellite instability-high (MSI-H) must also have received an anti-programmed cell death protein-1 mAb. Patients who received prior anti-HER2 targeting therapy were excluded. Patients received tucatinib 300 mg orally twice daily with trastuzumab (or a non-U.S. approved trastuzumab product) administered at a loading dose of 8 mg/kg intravenously on Day 1 of Cycle 1 followed by a maintenance dose of trastuzumab 6 mg/kg on Day 1 of each subsequent 21-day cycle. Patients were treated until disease progression or unacceptable toxicity. The major efficacy measures were overall response rate (ORR) and duration of response (DOR) as assessed by blinded independent central review (RECIST version 1.1.). ORR was 38% (95% CI: 28, 49) and median DOR was 12.4 months (95% CI: 8.5, 20.5). The most common adverse events (≥20%) were diarrhea, fatigue, rash, nausea, abdominal pain, infusion related reactions, and pyrexia. The most common laboratory abnormalities (≥20%) were increased creatinine, increased glucose, increased ALT, decreased hemoglobin, increased AST, increased bilirubin, increased alkaline phosphatase, decreased lymphocytes, decreased albumin, decreased leukocytes, and decreased sodium. The recommended tucatinib dose is 300 mg taken orally twice daily in combination with trastuzumab until disease progression or unacceptable toxicity. This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the Australian Therapeutic Goods Administration (TGA). The application review is ongoing at the other regulatory agency. This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment. This application was granted priority review and breakthrough therapy designation. FDA expedited programs are described in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics. Tukysa was granted orphan drug designation for the treatment of HER2+ colorectal cancer. Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088. For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov. For information on the COVID-19 pandemic, see the following resources: FDA: Coronavirus Disease 2019 (COVID-19) NCI: Coronavirus: What People With Cancer Should Know CDC: Coronavirus (COVID-19) Follow the Oncology Center of Excellence on Twitter @FDAOncology. Content current as of: 01/19/2023 Regulated Product(s) Drugs Oncology